Immune response to intranasal and intraperitoneal immunization with Kaposi's sarcoma-associated herpesvirus in mice.
A vaccine for Kaposi's sarcoma-associated herpesvirus (KSHV) is not currently available. To obtain the fundamental data in animals for vaccine development, KSHV particles were immunized to Balb/c mice through intraperitoneal and intranasal routes in the present study. Intranasal immunization with KSHV induced IgA to KSHV in not only serum, but also nasal wash fluid and saliva. A neutralization assay using recombinant KSHV that expressed green fluorescent protein revealed that nasal wash fluid and saliva from the KSHV-immunized mice neutralized KSHV infection to human embryonic kidney 293 cells in vitro in a dose-dependent manner to KSHV copies immunized. The serum and nasal wash fluid of KSHV-encoded K8.1 protein-immunized mice neutralized KSHV infection to 293 cells in vitro. These data suggest a possibility of mucosal vaccine for prophylaxis of KSHV infection.
Sakamoto
Kouta
K
Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
Asanuma
Hideki
H
Nakamura
Tomoyuki
T
Kanno
Takayuki
T
Sata
Tetsutaro
T
Katano
Harutaka
H
D000281:Administration, Intranasal; D000818:Animals; D057134:Antibodies, Neutralizing / Q000032:analysis; D002460:Cell Line; D005260:Female; D019288:Herpesvirus 8, Human / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis / Q000097:blood; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology; D012463:Saliva / Q000276:immunology; D044967:Serum / Q000276:immunology
D057134:Antibodies, Neutralizing; D022283:Herpesvirus Vaccines; D007070:Immunoglobulin A